The claimed statistic of '20-30%' for hair loss in COVID survivors is completely absent from this abstract. The abstract lists the most common symptoms at 6-month follow-up as: fatigue or muscle weakness (63%), sleep difficulties (26%), and anxiety or depression (23%). Hair loss is not mentioned anywhere in the abstract. Furthermore, this paper has been RETRACTED by The Lancet (with republication in 2023), which is a critical caveat that should disqualify it as a citable source. The claim appears to be fabricated or conflated with a different study entirely.

Suggested fix: The cited source (Huang et al., 2021, retracted) does not report hair loss data in its abstract. The most common symptoms reported were fatigue/muscle weakness (63%), sleep difficulties (26%), and anxiety/depression (23%). A different source would be needed to verify any claim about COVID-related hair loss prevalence.

The claim states an odds ratio (OR 3.2, 95% CI: 2.1-4.9) for 'Vascular Patterns & ICU' association. However, the source abstract is a case series report of 5 patients with severe COVID-19, describing histopathological findings of complement-mediated microvascular injury. This is a purely descriptive pathology study with NO quantitative statistical analysis, NO odds ratios, NO confidence intervals, and NO ICU outcome data presented. The abstract contains no comparative statistics between groups, no regression analyses, and no epidemiological measures of association. The claimed OR 3.2 with 95% CI appears completely fabricated as it does not match any content in the abstract and could not plausibly be derived from a 5-patient case series. The study design (case series, n=5) is fundamentally incapable of producing such a statistic.

The claim states 'Hair Loss in Women' with OR 2.6 and '30% vs 14% in men' as a confidence interval. This is completely fabricated. The source paper is about COVID-19 long-term consequences (fatigue, muscle weakness, sleep difficulties, anxiety, depression, pulmonary function) in hospitalized patients discharged from Jin Yin-tan Hospital in Wuhan, China. There is NO mention of hair loss anywhere in the abstract. The OR values in the abstract are 1.61, 4.60, 0.88, 1.77, 0.74, and 2.69 - none are 2.6. The percentages mentioned are 63% fatigue, 26% sleep difficulties, 23% anxiety/depression, and various percentages for pulmonary impairment by severity scale - nothing about 30% vs 14% for hair loss by sex. Additionally, this paper was RETRACTED and republished in 2023. The claim appears to be entirely invented or grossly misattributed.

The provided abstract contains NO quantitative prevalence data whatsoever. It describes a proposed classification system for COVID-19-associated cutaneous manifestations with six clinical patterns (urticarial rash, confluent erythematous/maculopapular/morbilliform rash, papulovesicular exanthem, chilblain-like acral pattern, livedo reticularis/racemosa-like pattern, and purpuric 'vasculitic' pattern), but does not report any specific percentages for overall COVID patients (12.8%), hospitalized patients (20.4%), or ICU patients with vascular patterns (33.0%). The abstract is purely descriptive of clinical patterns and pathophysiological hypotheses, with no epidemiological statistics. The specific numbers in the claim (12.8, 20.4, 33.0) appear to be fabricated or drawn from a different source, as they do not appear in this abstract and there is no quantitative data that could be misinterpreted to yield these figures.

The cited paper is a case series of 5 patients with severe COVID-19, examining pathological findings in skin and lung tissues. The abstract contains NO quantitative epidemiological data whatsoever - no hazard ratios, no confidence intervals, no mortality statistics, and no analysis of livedo/necrosis as a predictor of mortality. The paper is purely a descriptive pathology report with immunohistochemical findings. The claimed HR 2.8 (95% CI: 1.8-4.4) for 'Livedo/Necrosis Mortality' appears completely fabricated. With only 5 cases total, survival analysis with hazard ratios would be statistically impossible. The abstract discusses 3 patients with purpuric skin rash, but does not categorize these as 'livedo/necrosis' or perform any mortality risk analysis.

Suggested fix: This citation should be removed entirely. The paper does not contain any mortality risk statistics. If a claim about livedo/necrosis and mortality in COVID-19 is needed, a different source with appropriate epidemiological data must be found.